Virtus ETF Advisers LLC Ngm Biopharmaceuticals Inc Transaction History

Virtus ETF Advisers LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.72 - $5.4 $27,025 - $39,231	-7,265 Reduced 27.75%	18,916 $77,000
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $60,882 - $230,852	17,854 Added 214.41%	26,181 $131,000
Q3 2022 Nov 14, 2022	BUY	$12.59 - $17.67 $805 - $1,130	64 Added 0.77%	8,327 $109,000
Q2 2022 Aug 12, 2022	SELL	$10.58 - $17.5 $5,491 - $9,082	-519 Reduced 5.91%	8,263 $106,000
Q1 2022 May 16, 2022	SELL	$13.81 - $18.6 $7,167 - $9,653	-519 Reduced 5.58%	8,782 $134,000
Q4 2021 Feb 14, 2022	SELL	$17.26 - $22.02 $28,012 - $35,738	-1,623 Reduced 14.86%	9,301 $165,000
Q3 2021 Nov 15, 2021	SELL	$20.15 - $26.19 $11,626 - $15,111	-577 Reduced 5.02%	10,924 $230,000
Q2 2021 Aug 10, 2021	BUY	$15.06 - $30.03 $9,442 - $18,828	627 Added 5.77%	11,501 $227,000
Q1 2021 May 17, 2021	BUY	$24.99 - $31.93 $4,723 - $6,034	189 Added 1.77%	10,874 $316,000
Q4 2020 Feb 12, 2021	SELL	$16.21 - $31.44 $68,000 - $131,890	-4,195 Reduced 28.19%	10,685 $324,000
Q3 2020 Nov 13, 2020	SELL	$15.59 - $19.97 $31,694 - $40,599	-2,033 Reduced 12.02%	14,880 $237,000
Q2 2020 Aug 05, 2020	BUY	$11.97 - $23.47 $202,448 - $396,948	16,913 New	16,913 $334,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.